Source:http://linkedlifedata.com/resource/pubmed/id/18613768
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
8
|
| pubmed:dateCreated |
2008-7-10
|
| pubmed:abstractText |
Apomab is a pro-apoptotic anticancer agonist monoclonal antibody against Death receptor 5 (DR5)/TNF-related apoptosis inducing ligand-receptor 2 (TRAIL-R2).
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
1744-7682
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
8
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1167-76
|
| pubmed:meshHeading | |
| pubmed:year |
2008
|
| pubmed:articleTitle |
Apomab: an agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors.
|
| pubmed:affiliation |
Developmental Therapeutics and Thoracic Oncology Programs, Department of Medical Oncology, University of Colorado Denver, Aurora, CO 80045-0508, USA. Ross.Camidge@UCHSC.edu
|
| pubmed:publicationType |
Journal Article
|